Insights

Strategic partnerships 3T Biosciences actively pursues collaborations with big pharma and biotech leaders, evidenced by multiple Boehringer Ingelheim partnerships and a notable collaboration with Parker Institute for Cancer Immunotherapy. This indicates a favorable openness to licensing, co-development, and technology collaboration opportunities for accelerating programs.

Clinical leadership Recent appointments to chief medical officer and chief research officer, along with a senior VP for early development, signal a strong emphasis on advancing a TCR-based therapeutics pipeline toward clinical progression. Target engagement with their translational and clinical leadership teams could accelerate discussions on partnering clinical strategies or shared development costs.

Immunotherapy focus Specialization in next-generation immunotherapies for solid tumors and immune-mediated diseases positions 3T as a candidate for opportunities in cellular therapy, TCR-based programs, and next-generation safety/effectiveness improvements. Sales conversations can emphasize collaboration on platform capabilities, patient stratification, and translational biomarkers.

Funding and scale With revenue in the tens of millions and total funding around fifty-two million, 3T operates with moderate scale and growth potential. This suggests readiness for co-development funding, milestone-driven partnerships, and licensing deals that align with mid-stage to late-stage program financing.

Strategic geography Presence in California with established biotech hubs and recent leadership appointments indicate readiness for U.S. market-focused collaborations, regulatory strategy alignment, and potential expansion into European partnerships through existing Boehringer Ingelheim ties and global translational capabilities.

Similar companies to 3T Biosciences

3T Biosciences Tech Stack

3T Biosciences uses 8 technology products and services including iCIMS, Amazon Web Services, Squarespace, and more. Explore 3T Biosciences's tech stack below.

Media & News

3T Biosciences's Email Address Formats

3T Biosciences uses at least 3 email formats:
3T Biosciences Email FormatsExamplePercentage
First.Last@3tbiosciences.comJohn.Doe@3tbiosciences.com
86%
Last@3tbiosciences.comDoe@3tbiosciences.com
11%
First@3tbiosciences.comJohn@3tbiosciences.com
3%

Frequently Asked Questions

What is 3T Biosciences's official website and social media links?

Minus sign iconPlus sign icon
3T Biosciences's official website is 3tbiosciences.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does 3T Biosciences generate?

Minus sign iconPlus sign icon
As of October 2026, 3T Biosciences's annual revenue is estimated to be $10M - $25M.

What is 3T Biosciences's SIC code and NAICS code?

Minus sign iconPlus sign icon
3T Biosciences's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does 3T Biosciences have currently?

Minus sign iconPlus sign icon
As of October 2026, 3T Biosciences has approximately 25 employees across 2 continents, including North America and Europe. Key team members include Chief Medical Officer: B. K., Interim Ceo: J. C. and Vp, Head Of Clinical Operations: R. V. B. Explore 3T Biosciences's employee directory with LeadIQ.

What industry does 3T Biosciences belong to?

Minus sign iconPlus sign icon
3T Biosciences operates in the Biotechnology Research industry.

What technology does 3T Biosciences use?

Minus sign iconPlus sign icon
3T Biosciences's tech stack includes iCIMS, Amazon Web Services, Squarespace, WordPress, Amazon Redshift, OpenAI, Asana and DocuSign.

What is 3T Biosciences's email format?

Minus sign iconPlus sign icon
3T Biosciences's email format typically follows the pattern of First.Last@3tbiosciences.com. Find more 3T Biosciences email formats with LeadIQ.

How much funding has 3T Biosciences raised to date?

Minus sign iconPlus sign icon
As of October 2026, 3T Biosciences has raised $52M in funding. The last funding round occurred on Sep 25, 2022 for $40M.

When was 3T Biosciences founded?

Minus sign iconPlus sign icon
3T Biosciences was founded in 2017.
3T Biosciences logo

3T Biosciences

Biotechnology ResearchCalifornia, United States11-50 Employees

3T Biosciences is a biotechnology research company focused on immunotherapy, headquartered at 681 Gateway Boulevard, South San Francisco, California 94080. The company develops next-generation therapies designed to treat solid tumors and other immune-mediated diseases by leveraging the immune system to recognize and destroy cancer cells. It employs 11 to 50 people. In January 2026, Behzad Kharabi, M.D., was appointed chief medical officer, and the company has engaged in partnerships with Boehringer Ingelheim to develop next-generation cancer immunotherapies. Reported revenue is in the range of $10 million to $25 million, and total funding is around $40 million.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
11-50

Section iconFunding & Financials

  • $52M

    3T Biosciences has raised a total of $52M of funding over 3 rounds. Their latest funding round was raised on Sep 25, 2022 in the amount of $40M as a Series A.

  • $10M - $25M

    3T Biosciences's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.